Is Portage Biotech Stock a Good Investment?
Portage Biotech Investment Advice | PRTG |
- Examine Portage Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Portage Biotech's leadership team and their track record. Good management can help Portage Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Portage Biotech's business and its evolving consumer preferences.
- Compare Portage Biotech's performance and market position to its competitors. Analyze how Portage Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Portage Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Portage Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Portage Biotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Portage Biotech is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Portage Biotech Stock
Researching Portage Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 30.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 68.17. Portage Biotech last dividend was issued on the 4th of June 2020. The entity had 1:20 split on the 15th of August 2024.
To determine if Portage Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Portage Biotech's research are outlined below:
| Portage Biotech is way too risky over 90 days horizon | |
| Portage Biotech appears to be risky and price may revert if volatility continues | |
| Portage Biotech has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (75.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Portage Biotech currently holds about 21.18 M in cash with (14.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25. | |
| Portage Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Insider Confidence Portage Directors Invest 2.15M in Strategic Private Placement - StockTitan |
Portage Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Portage Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Portage Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 29th of July 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of July 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Portage Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Portage Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-23 | 2021-09-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2021-07-29 | 2021-06-30 | -0.21 | -0.25 | -0.04 | 19 | ||
2023-08-30 | 2023-06-30 | -0.24 | -0.33 | -0.09 | 37 | ||
2022-08-28 | 2022-06-30 | -0.3 | -0.13 | 0.17 | 56 | ||
2023-03-01 | 2022-12-31 | -0.23 | -0.44 | -0.21 | 91 | ||
2022-11-29 | 2022-09-30 | -0.29 | -0.06 | 0.23 | 79 | ||
2024-02-28 | 2023-12-31 | -0.27 | 0.01 | 0.28 | 103 | ||
2022-06-01 | 2022-03-31 | -0.28 | -0.56 | -0.28 | 100 |
Know Portage Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Portage Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Portage Biotech backward and forwards among themselves. Portage Biotech's institutional investor refers to the entity that pools money to purchase Portage Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Princeton Global Asset Management Llc | 2024-12-31 | 8.0 | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 7.0 | The Toronto-dominion Bank | 2024-09-30 | 0.0 | Carolinas Wealth Consulting Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Ieq Capital, Llc | 2024-09-30 | 0.0 | Lakeview Capital Partners, Llc | 2024-09-30 | 98.5 K | Virtu Financial Llc | 2024-09-30 | 10.9 K | Renaissance Technologies Corp | 2024-09-30 | 10.1 K | Connective Capital Management Llc | 2024-09-30 | 7.9 K | Ubs Group Ag | 2024-09-30 | 2.5 K |
Portage Biotech's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.26 M.Market Cap |
|
Portage Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.72) | (8.28) | |
| Return On Capital Employed | (3.35) | (3.52) | |
| Return On Assets | (8.72) | (8.28) | |
| Return On Equity | (16.86) | (17.70) |
Determining Portage Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Portage Biotech is a good buy. For example, gross profit margin measures Portage Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Portage Biotech's profitability and make more informed investment decisions.
Evaluate Portage Biotech's management efficiency
Portage Biotech has return on total asset (ROA) of (0.1942) % which means that it has lost $0.1942 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9103) %, meaning that it created substantial loss on money invested by shareholders. Portage Biotech's management efficiency ratios could be used to measure how well Portage Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The Portage Biotech's current Return On Tangible Assets is estimated to increase to -8.28. The current Return On Capital Employed is estimated to decrease to -3.52. The Portage Biotech's current Other Current Assets is estimated to increase to about 3.2 M, while Total Assets are projected to decrease to roughly 8.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.19 | 0.18 | |
| Net Current Asset Value | -443.4 K | -465.6 K | |
| Tangible Book Value Per Share | 0.19 | 0.18 | |
| Enterprise Value Over EBITDA | (13.90) | (14.60) | |
| Price Book Value Ratio | 64.32 | 61.11 | |
| Enterprise Value Multiple | (13.90) | (14.60) | |
| Price Fair Value | 64.32 | 61.11 | |
| Enterprise Value | 347.8 M | 365.1 M |
Understanding the operational decisions made by Portage Biotech management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 99.478 |
Basic technical analysis of Portage Stock
As of the 2nd of February, Portage Biotech holds the Coefficient Of Variation of 2764.05, risk adjusted performance of 0.04, and Semi Deviation of 7.22. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Portage Biotech, as well as the relationship between them. Please check Portage Biotech information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Portage Biotech is priced some-what accurately, providing market reflects its current price of 4.41 per share. Given that Portage Biotech has jensen alpha of 1.55, we recommend you to check out Portage Biotech's recent market performance to make sure the company can sustain itself at a future point.Portage Biotech's Outstanding Corporate Bonds
Portage Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Portage Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Portage bonds can be classified according to their maturity, which is the date when Portage Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Portage Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Portage Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.04 | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 7.44 | |||
| Semi Deviation | 7.22 | |||
| Downside Deviation | 8.04 | |||
| Coefficient Of Variation | 2764.05 | |||
| Standard Deviation | 23.07 | |||
| Variance | 532.23 | |||
| Information Ratio | 0.0328 | |||
| Jensen Alpha | 1.55 | |||
| Total Risk Alpha | (1.06) | |||
| Sortino Ratio | 0.094 | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 204.1 | |||
| Value At Risk | (12.61) | |||
| Potential Upside | 8.33 | |||
| Downside Variance | 64.65 | |||
| Semi Variance | 52.09 | |||
| Expected Short fall | (9.51) | |||
| Skewness | 7.15 | |||
| Kurtosis | 55.8 |
| Risk Adjusted Performance | 0.04 | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 7.44 | |||
| Semi Deviation | 7.22 | |||
| Downside Deviation | 8.04 | |||
| Coefficient Of Variation | 2764.05 | |||
| Standard Deviation | 23.07 | |||
| Variance | 532.23 | |||
| Information Ratio | 0.0328 | |||
| Jensen Alpha | 1.55 | |||
| Total Risk Alpha | (1.06) | |||
| Sortino Ratio | 0.094 | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 204.1 | |||
| Value At Risk | (12.61) | |||
| Potential Upside | 8.33 | |||
| Downside Variance | 64.65 | |||
| Semi Variance | 52.09 | |||
| Expected Short fall | (9.51) | |||
| Skewness | 7.15 | |||
| Kurtosis | 55.8 |
Consider Portage Biotech's intraday indicators
Portage Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Portage Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Portage Biotech Corporate Filings
| 31st of January 2025 Other Reports | ViewVerify | |
6K | 30th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 14th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
| 23rd of August 2024 Other Reports | ViewVerify |
Portage Stock media impact
Far too much social signal, news, headlines, and media speculation about Portage Biotech that are available to investors today. That information is available publicly through Portage media outlets and privately through word of mouth or via Portage internal channels. However, regardless of the origin, that massive amount of Portage data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Portage Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Portage Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Portage Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Portage Biotech alpha.
Portage Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Portage Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Portage Biotech Corporate Management
| MD MBA | CEO Board | Profile | |
| Allan CPA | Chief Officer | Profile | |
| Adam Melero | Controller | Profile | |
| EunJae CPA | Chief Officer | Profile | |
| Robert Kramer | Chief Officer | Profile | |
| Brian Wiley | Chief Officer | Profile | |
| Andrea Park | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Portage Biotech's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.